Zenith Epigenetics

almost 8 years ago

I had to hit google translate so, it is somewhat lost in translation but more importantly is the title " Zenith Epigenetics to develp anti-tumor drug and the author... Muneaki Hashimoto .

https://bio.nikkeibp.co.jp/atcl/news/p1/16/10/25/01757/ (I hit google translate at this point)

Zenith Epigenetics, Inc. to develop a BET inhibitor anti-tumor drugs

「フェーズII開始前にパートナーを得たい」 "I want to give a partner in the previous phase II start"

(2016.10.25 01:33) (2016.10.25 01:33)

橋本宗明 Muneaki Hashimoto

シェア share

BET (bromodomain and extra-terminal)ファミリー蛋白質は抗癌剤の標的になると見られる蛋白質の1つである。 BET (bromodomain and extra-terminal) family proteins is one of the proteins found to be a target for anti-cancer agents. このBET蛋白質の阻害薬を開発するカナダ・カルガリーに本社を置くZenith Epigenetics社のチーフビジネスオフィサーのSanjay Lakhotia氏は2016年10月12日、本誌の取材に応じ、フェーズII以降の開発を共同で進めるパートナーを求めていることを明らかにした。 This Sanjay Lakhotia's BET protein to develop inhibitors of place in Calgary, Canada headquartered Zenith Epigenetics's chief business officer, October 12, 2016, according to the journal of the coverage, promote the development of the subsequent Phase II in collaboration It was it clear that seeking a partner.